# DESCRIPTION

## FIELD OF THE INVENTION

- relate to novel binding interactions

## BACKGROUND OF THE INVENTION

- describe S100A9 protein

## SUMMARY OF THE INVENTION

- introduce novel binding interactions

## DESCRIPTION OF THE SEQUENCES MENTIONED HEREIN

- list sequence IDs

## DETAILED DESCRIPTION OF THE INVENTION

- introduce method for identifying therapeutic compounds
- describe binding assays for identifying compounds
- outline characteristics of compounds to be selected
- describe forms and variants of S100A9 and ligand
- discuss post-translational modifications and purification of S100A9 and ligand

### Homologues

- define homologues of sequences and calculate homology

### Further Testing of the Identified Compound

- describe further testing of identified compounds in cell-based assays and animal models

### The Antibody of the Invention

- describe antibody 43/8
- define epitope on S100A9
- specify antibody characteristics
- outline therapeutic uses

### Administration

- formulate compounds into pharmaceutical composition
- describe administration routes and dosage

### Proteomic Screen

- describe proteomic screen results

### The Biacore Assay

- describe Biacore assay system

### The Immobilization of RAGE to a Chip

- describe immobilization of RAGE to a chip

### The Novel Interaction S100A9 and RAGE

- demonstrate S100A9 binding to RAGE
- compare binding of S100A9 to RAGE with other S100 proteins
- modulate S100A9 to RAGE interaction with compounds
- analyze effects of S100A9 binding compounds on immune cells

## Materials and Methods

### Compound A

- synthesize compound A

### Biosensor Analysis

- describe SPR technology

### Immobilization of RAGE

- immobilize RAGE on sensor chip

### Immobilization of TLR4/MD-2 Complex

- immobilize TLR4/MD-2 on sensor chip

### Competition Assay

- describe competition assay protocol

### Evaluation of Binding Data

- evaluate binding data using BIAevaluation software

### Purification of Splenic DCs and Human PBMCs

- purify splenic DCs and human PBMCs

### MLR Reactions

- perform MLR reactions

### Analysis of Cell Subsets by Flow Cytometry

- analyze cell subsets by flow cytometry

## Autoimmune Disease Models

- describe autoimmune disease models

### The Nonobese Diabetic (NOD) Mouse Model for Autoimmune Insulin-Dependent Diabetes Mellitus (IDDM)

- describe NOD mouse model

## Generation of Anti-S100A9 Monoclonal Antibody 43/8

- generate monoclonal antibody

### BIACORE™ Assays Demonstrates the Binding Ability of the Anti-S100A9 mAb 43/8

- demonstrate binding ability

### The Anti-S100A9 mAb 43/8 is Specific to Human S100A9

- demonstrate specificity

### The Anti-S100A9 mAb 43/8 Blocks Binding of Human S100A9 to TLR4/MD-2

- demonstrate blocking ability

### The Anti-S100A9 Antibody Recognizes a Unique Epitope

- demonstrate unique epitope recognition

### The Anti-S100A9 mAb 43/8 Stimulates TNFα-Production in Peripheral Blood Mononuclear Cells

- demonstrate TNFα production stimulation

### The Anti-S100A9 mAb 43/8 Stimulates an NFκB Reporter Gene in LNCaP Cells

- demonstrate NFκB reporter gene stimulation

## Conclusion

- summarize antibody properties

### Compound A is an Efficient Modulator of S100A9 Binding to RAGE and TLR4

- demonstrate Compound A modulating ability

